Enter your email address:

Delivered by FeedBurner

Alembic Pharma receives 4 observations from USFDA for Panelav facility

"The US Food and Drug Administration (USFDA) has conducted an
inspection at Alembic Pharmaceuticals general oral solid formulation
facility located at Panelav from 9-13 March, 2020," the drug firm said
in a filing to the BSE. This was a scheduled inspection, and at the
end of the inspection, the USFDA issued a Form 483 with four
procedural observations.



Post a Comment